Key Points for Decision Makers {#FPar1}
==============================

Secukinumab 150 mg at list price may represent a cost-effective treatment option from the perspective of the UK National Health Service for patients with active psoriatic arthritis who are tumour necrosis factor inhibitor naïve, do not have concomitant moderate-to-severe psoriasis and who have responded inadequately to previous conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).Secukinumab 150 mg was associated with an incremental cost effectiveness ratio of less than £30,000 per quality-adjusted life year gained versus standard of care in the subpopulation of patients who responded inadequately to one prior csDMARD, and in some cases dominated tumour necrosis factor inhibitors in the two or more prior csDMARD subpopulation.The availability of published subgroup data for all comparators would reduce uncertainty in cost effectiveness analyses of biologics at different stages of the treatment pathway in psoriatic arthritis. In the absence of such data for this evaluation, assumptions on biologic efficacy (e.g. for the second-line biologic in the treatment sequencing scenario) were required.

Introduction {#Sec1}
============

Psoriatic arthritis (PsA) is a chronic, progressive, inflammatory condition that is characterised by manifestations of the joints and skin \[[@CR1]\]. PsA can lead to irreversible joint damage, which can be highly debilitating for patients, and is associated with a considerable economic burden \[[@CR2], [@CR3]\]. Conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate, represent standard care for the early management of patients with active PsA, with biologics, such as tumour necrosis factor inhibitors (TNFis), providing a treatment option for those patients who have responded inadequately to prior csDMARDs \[[@CR1], [@CR4], [@CR5]\]. Initiation of biologics in the treatment pathway is dependent on the number of prior csDMARDs received, amongst other factors \[[@CR5], [@CR6]\]. According to treatment guidelines from the British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR) (2012), TNFi therapy is typically recommended for patients who have failed at least two csDMARDs \[[@CR7]\]. However, the guidelines also recommend that TNFis may be considered after failure of only one csDMARD if there is evidence of adverse prognostic factors, such as the presence of five or more swollen joints in association with elevated C-reactive protein persisting for ≥ 3 months, or structural joint damage due to disease \[[@CR7]\]. More recent guidelines from the European League Against Rheumatism (EULAR) (2015) recommend that biologics should be considered following an inadequate response to at least one csDMARD for patients with peripheral arthritis \[[@CR8]\].

Secukinumab is a fully human immunoglobulin IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin (IL)-17A \[[@CR9]\]. The efficacy and tolerability of secukinumab in adult patients with active PsA despite prior csDMARDs has been demonstrated in two phase 3 placebo-controlled trials (FUTURE 1 and FUTURE 2) \[[@CR10], [@CR11]\]. In both trials, secukinumab 150 mg met the same primary endpoint, with a higher proportion of secukinumab-treated patients achieving an American College of Rheumatology 20 response compared to the placebo group at week 24 \[[@CR10], [@CR11]\]. Response to treatment in both trials was also evaluated using the Psoriatic Arthritis Response Criteria (PsARC), which is used to define treatment response in guidance from the National Institute for Health and Care Excellence (NICE) \[[@CR5], [@CR6], [@CR10], [@CR11]\]. The Psoriasis Area Severity Index (PASI) and Health Assessment Questionnaire (HAQ) were used to assess skin outcomes and functional ability, respectively.

The cost effectiveness of secukinumab as a treatment for patients with psoriasis in the UK has been evaluated previously and has also been demonstrated in TNFi-naïve and TNFi-experienced PsA patients in analyses conducted from the Canadian healthcare perspective \[[@CR12], [@CR13]\]. Here, the cost effectiveness of secukinumab as a treatment for active PsA in adults who have responded inadequately to prior csDMARDs has been evaluated from the perspective of the UK National Health Service (NHS). As biologics may be initiated at various places in the treatment pathway, separate analyses have been conducted based on the number of prior csDMARDs to which patients have responded inadequately, in a similar manner to the UK analysis by Corbett et al. \[[@CR14]\]. The analyses presented include hitherto unpublished utilities derived from a novel algorithm. Furthermore, an alternative approach to modelling second-line biologics has been explored in scenario analyses.

Methods {#Sec2}
=======

Population, Interventions and Comparators {#Sec3}
-----------------------------------------

The economic evaluation considered adults with active PsA who were TNFi-naive and without concomitant moderate-to-severe psoriasis, and who had responded inadequately to prior csDMARDs. Two patient subpopulations were considered separately in the analysis: those who had (a) failed treatment with one prior csDMARD (1 prior csDMARD) and (b) failed treatment with two or more prior csDMARDs (≥ 2 prior csDMARDs). For both subpopulations, patients entered the model with an average age of 48 years and had a mean weight of 87.11 kg (standard deviation, 19.66); 48% of the modelled cohort were male. These demographic characteristics were based on the randomised trial population of FUTURE 2 \[[@CR11]\].

The intervention of interest was secukinumab 150 mg, which is the licensed dose for patients without concomitant moderate-to-severe psoriasis and for those who are TNFi naïve \[[@CR9]\]. This dose was included in FUTURE 2 and inputs regarding patient characteristics and treatment response have been derived from this trial rather than FUTURE 1, which used an unlicensed intravenous loading dose \[[@CR10], [@CR11]\].

The relevant comparators for each subpopulation were selected based on published guidance from UK Health Technology Assessment (HTA) bodies for the treatment of active PsA following an inadequate response to prior csDMARDs \[[@CR4]--[@CR6], [@CR15], [@CR16]\]. Current NICE and Scottish Medicines Consortium (SMC) recommendations for biologics require patients to have had an inadequate response to two or more csDMARDs; therefore the only comparator included for the 1 prior csDMARD subpopulation was standard of care (SoC) (methotrexate, 25 mg per week, in accordance with 2015 EULAR guidelines) \[[@CR4]--[@CR6], [@CR8], [@CR15], [@CR16]\]. For the ≥ 2 prior csDMARDs subpopulation, the TNFis (adalimumab, certolizumab pegol, etanercept, infliximab, and golimumab) were included, with each TNFi modelled according to the licensed dose. The golimumab dose (50 mg or 100 mg) did not result in significant differences in efficacy as part of a network meta-analysis (NMA), and so the 50 mg results were used. Ustekinumab was not included as a comparator as it is only recommended by NICE and the SMC for patients who have either had treatment with one or more TNFis already or for whom treatment with a TNFi is contraindicated \[[@CR6], [@CR17], [@CR18]\]. For etanercept and infliximab, biosimilar products are available in the UK, and so both originator and biosimilar products were included as separate comparators in the analysis, with only drug acquisition costs altered for the biosimilar products. Patients receiving biologics were assumed to also receive SoC.

Model Structure {#Sec4}
---------------

The model consisted of a 3-month decision tree that led into a Markov state transition model with three health states: Maintenance Treatment, SoC, and Death (see Fig. [1](#Fig1){ref-type="fig"}). This structure is consistent with previous cost effectiveness analyses of biologics for PsA, including Rodgers et al., which has formed the basis for cost effectiveness analyses for UK HTA \[[@CR4]--[@CR6], [@CR14], [@CR19], [@CR20]\].Fig. 1Model structure. **a** Decision tree model structure. Responders were those patients who achieved a PsARC response at 3 months. **b** Markov model structure. *PsARC* psoriatic arthritis response criteria, *SoC* standard of care

Patients entered the decision tree on treatment initiation and response to therapy using PsARC was assessed after 3 months. The timing of the assessment was based on 2012 BSR/BHPR guideline recommendations \[[@CR7]\]. Patients were defined as responders or non-responders depending on whether they had achieved a PsARC response at 3 months, with responders continuing treatment with biologics in the Markov model (Maintenance Treatment) and non-responders receiving SoC (as shown in Fig. [1](#Fig1){ref-type="fig"}).

During each subsequent 3-month cycle, patients in the Maintenance Treatment state could continue treatment and remain in this state, discontinue biologic therapy and thus transition to the SoC state, or die and thus enter the absorbing Death state (see Fig. [1](#Fig1){ref-type="fig"}). Withdrawal from biologic therapy was based on FUTURE 2 trial all-cause discontinuation rates for secukinumab 150 mg, with rates specified in year 1 (14.0%) and all subsequent years (11.6%). In line with the assumption made by Corbett et al., a common discontinuation rate was assumed for all biologics \[[@CR14]\]. Patients in the SoC state were modelled to receive SoC until death and could not transition back to the Maintenance Treatment state.

The model tracked disease progression via changes over time in HAQ and PASI scores, with utility and disease-related costs accrued throughout the time horizon based on these scores. In utilising both HAQ and PASI scores, the model considers the impact of both arthritic and skin components of PsA on patients' health-related quality of life and healthcare resource use. Treatment effect was modelled as the change from baseline in HAQ and the distribution of PASI scores at 3 months (see Sect. [2.3](#Sec5){ref-type="sec"}), with the former conditioned on whether or not a patient had achieved a PsARC response at 3 months. In order to isolate the clinical effect of each treatment from the general benefit of trial participation, both PASI and HAQ scores were adjusted to reflect the response observed by patients receiving placebo, as per Rodgers et al. \[[@CR20]\]. PASI and HAQ scores were assumed to remain unchanged whilst patients continued to receive biologic therapy in the Maintenance Treatment state, again consistent with Rodgers et al. \[[@CR20]\]. Sustained improvements in HAQ have also been reported in FUTURE 2 \[[@CR11]\]. Patients who withdrew from biologic therapy and entered the SoC state were modelled to rebound to baseline PASI and HAQ scores in the cycle after treatment withdrawal (i.e. rebound was set equal to initial gain in the base case analysis). In each subsequent cycle, these patients were modelled to experience a steady, linear increase in their HAQ score (0.018 per cycle) until death or the maximum HAQ score of three was reached, to reflect worsening arthritis whilst not receiving biologics \[[@CR19], [@CR20]\].

The model was conducted over a 40-year time horizon from the perspective of the UK NHS. This time horizon was chosen to reflect the chronic nature of the condition. Costs and utilities were accrued across the time horizon and were assigned to health states either directly (e.g. cost associated with biologics or SoC) or via other factors related to treatment, such as disease scores (HAQ and PASI).

Modelling of Health Outcomes {#Sec5}
----------------------------

### Baseline Clinical Characteristics {#Sec6}

For both subpopulations included in the economic evaluation, baseline HAQ (1.209) and PASI (7.304) scores were based on those of randomised patients in the FUTURE 2 trial who had not previously received TNFi therapy.

### PsARC Responses and PASI Distribution at 3 Months {#Sec7}

For secukinumab and SoC in the 1 prior csDMARD subpopulation, PsARC response and the distribution of patients with PASI response \< 50, 50--74, 75--89 and 90--99 at 3 months were based on post hoc subgroup analyses from the randomised, placebo-controlled FUTURE 2 trial (see Table 4a in the Electronic Supplementary Material). For the ≥ 2 prior csDMARDs subpopulation, response to treatment at the end of the initial 3-month period (PsARC and PASI) was based on the results of a systematic literature review (SLR) and NMA of clinical evidence for licensed doses of biologics for PsA (see Table 5, Electronic Supplementary Material). A similar NMA is reported by McInnes et al. \[[@CR21]\]. Differences across each PASI response category were statistically significant for secukinumab 150 mg versus certolizumab pegol and etanercept, but no significant differences for secukinumab versus comparators were reported for PsARC.

In modelling the change from baseline in PASI based on response category, it was assumed that patients would achieve the minimal reduction for each category (i.e. PASI 75 responders would achieve at least a 75% reduction in baseline PASI), as per Rodgers et al. \[[@CR20]\].

### Changes in HAQ at 3 Months {#Sec8}

The extent to which HAQ scores were reduced in the model was conditional on whether or not a PsARC response had been achieved at 3 months. For secukinumab, the reduction in HAQ score on treatment response for the 1 prior csDMARD and ≥ 2 prior csDMARDs subpopulations were based on corresponding post hoc subgroup analyses of FUTURE 2 (see Table 4b; Electronic Supplementary Material). A response-dependent change in HAQ score for SoC is also modelled based on that observed in the FUTURE 2 subgroup analyses. For TNFis, changes in HAQ were derived from another published cost effectiveness analysis \[[@CR19]\]. As certolizumab pegol was not included in this previous cost effectiveness analysis, the average change in HAQ for all other TNFis was used in the absence of any published data.

### Adverse Events {#Sec9}

Serious infection was the only adverse event included in the model, with the probability of an event in each 3-month cycle based on trial data for each intervention (see Table 4c; Electronic Supplementary Material) \[[@CR11], [@CR22]--[@CR26]\]. This adverse event was selected due to the increased risk of infection with biologics targeting immune pathways \[[@CR9], [@CR27]\]. Five percent of serious infections were assumed to be cases of tuberculosis, which were modelled to have higher costs per event than other serious infections \[[@CR28]\].

### Mortality {#Sec10}

Baseline mortality in the model was determined using mortality rates from the general population life tables \[[@CR29]\]. This baseline rate was then adjusted for the gender-specific relative risk of death for patients with PsA (male 1.65 and female 1.59), as done in previous cost effectiveness analyses \[[@CR20], [@CR30]\].

Utility Inputs {#Sec11}
--------------

Utility values for the model were derived from a linear mixed model that used patient-level EuroQol 5-Dimensions (3-Level; EQ-5D-3L) data from FUTURE 2 and estimated utility based on absolute HAQ and PASI scores, baseline EQ-5D, age, gender and prior TNFi status (see Table 6; Electronic Supplementary Material).

This approach reflects the clinical experience of patients, with lower HAQ and PASI scores being associated with higher utility values. No disutility was modelled for the occurrence of adverse events, as per the assumption made by Rodgers et al. \[[@CR20]\].

Cost and Resource Use Inputs {#Sec12}
----------------------------

The evaluation was conducted from the perspective of the UK NHS and so only direct costs incurred by the NHS were included in the analysis. These included drug acquisition costs (list price for all interventions), administration and monitoring costs, disease-related costs and costs associated with the management of serious infections (see Table 7; Electronic Supplementary Material). The cost year was 2017 and, where required, costs were inflated using the Hospital and Community Health Services Index \[[@CR31]\].

Model Outcomes {#Sec13}
--------------

The model outcomes included the total cost and quality-adjusted life years (QALYs) accrued over the model time horizon, with both costs and QALYs discounted at a 3.5% annual rate, as is standard practice for UK cost effectiveness analyses \[[@CR32]\]. A half-cycle correction using the life table method was applied to all outcomes, with the exception that drug costs and QALYs were not half-cycle corrected in the first cycle of the Markov model, as the treatment responses and resulting utility changes were achieved within 3 months. Cost effectiveness was assessed in terms of the incremental cost effectiveness ratio (ICER), which describes the incremental costs per QALY gained for secukinumab versus each comparator. A fully incremental analysis has also been conducted for the ≥ 2 prior csDMARDs subpopulation.

Sensitivity and Scenario Analyses {#Sec14}
---------------------------------

One-way deterministic sensitivity analyses were conducted for each subpopulation to identify parameters which had the greatest influence on cost effectiveness results. Given secukinumab was generally either dominant or associated with a 'south-west' ICER, changes in cost effectiveness were assessed in terms of net monetary benefit, with one QALY valued at £30,000 to represent the upper limit of cost effectiveness that may be considered by UK decision makers. Probabilistic sensitivity analyses were also conducted in which all model parameters were varied simultaneously over 1000 simulations. Inputs for these sensitivity analyses are presented in Table 8 (see the Electronic Supplementary Material).

To test alternative assumptions, various scenarios were conducted including: varying the time horizon used; including PASI in the criteria for treatment response; removing the placebo adjustment effect on HAQ and PASI; assuming that HAQ rebound is equal to natural history at the time of discontinuation; and using utility values from Rodgers et al. \[[@CR20]\]. Additional scenarios were also conducted in the ≥ 2 prior csDMARDs subpopulation only, including: the use of a second-line biologic on discontinuation, as recommended in the 2012 BSR/BHPR guidelines; the inclusion of publicly-available Patient Access Schemes (PASs) for certolizumab pegol and golimumab (no PASs exist for the other biologics, with the exception of a confidential PAS for secukinumab); and assuming equivalence with secukinumab for any non-significant differences in PASI and PsARC \[[@CR4], [@CR7], [@CR15]\]. As part of the treatment sequencing scenarios, the second-line biologic was modelled as a weighted average of all biologics (other than that received first-line) based on estimated use of each biologic in clinical practice. Scenarios were conducted in which (a) biologics were assumed to have equivalent efficacy in first- and second-line, and (b) a 20% reduction in each efficacy input was modelled in the second line.

Model Validation {#Sec15}
----------------

Quality control for model internal validity was performed through independent review of the model by a different health economist to those responsible for initial construction of the model. A rheumatologist (B. K.) specialising in PsA was also involved in the development of the model to ensure that the underlying assumptions and model outcomes were reflective of UK clinical practice.

Results {#Sec16}
=======

Base Case Results {#Sec17}
-----------------

In the 1 prior csDMARD subpopulation, secukinumab was associated with a QALY gain of 1.030 versus SoC, but was also associated with higher total costs over the 40-year model time horizon (incremental cost of £29,619; see Table [1](#Tab1){ref-type="table"}a). The ICER for secukinumab at list price versus SoC in the 1 prior csDMARD subpopulation was £28,748 per QALY gained.Table 1Base case deterministic cost effectiveness results (with incremental results for secukinumab vs each comparator and results of fully incremental analyses)a. 1 prior csDMARDInterventionTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£ per QALY)SEC91,0627.837SoC61,4436.80729,6191.03028,748b. ≥ 2 prior csDMARDsInterventionTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£ per QALY), pairwiseICER (£ per QALY), fully incrementalSEC93,1137.9985680ADA90,9937.61521200.3735680--CZP101,2467.913−81340.074Dominated by SECDominatedETN (originator)100,1347.984−70220.004Dominated by SECDominatedETN (biosimilar)96,5097.984−33960.004Dominated by SECDominatedGOL104,7727.709−11,6590.279Dominated by SECDominatedINF (originator)128,9498.013− 35,837− 0.0261,403,849^a^Extendedly dominatedINF (biosimilar)122,4098.013− 29,296− 0.0261,147,641^a^1,147,641Incremental results are presented for SEC vs comparator(s). In the ≥ 2 prior csDMARD subpopulation, the fully incremental analysis found all interventions other than SEC, ADA (least costly) and INF (biosimilar) to be dominated or extendedly dominated (INF \[originator\]). The ICER for SEC vs ADA was £5680 per QALY gained, and the ICER for INF (biosimilar) vs SEC was £1,147,641 per QALY gained. INF (originator) was extendedly dominated by SEC and INF (biosimilar)*ADA* adalimumab, *csDMARD* conventional systemic disease-modifying anti-rheumatic drug, *CZP* certolizumab pegol, *ETN* etanercept, *GOL* golimumab, *ICER* incremental cost effectiveness ratio, *INF* infliximab, *QALY* quality-adjusted life year, *SEC* secukinumab, *SoC* standard of care^a^ The ICERs for SEC vs INF (originator and biosimilar) land in the south-west quadrant of the cost effectiveness plane (negative incremental costs and negative incremental QALYs). Therefore, the ICER is a positive value and should be interpreted as the cost savings per QALY foregone with SEC vs INF

In the ≥ 2 prior csDMARDs subpopulation, secukinumab dominated certolizumab pegol, etanercept and golimumab (see Table [1](#Tab1){ref-type="table"}b for pairwise comparisons and fully incremental results). Secukinumab was also associated with lower total costs versus infliximab, but produced marginally fewer QALYs (0.026) over the model time horizon. The ICERs for secukinumab versus infliximab corresponded to savings in excess of £1 million per QALY foregone with secukinumab, with the ICER being positioned in the south-west quadrant of the cost effectiveness plane. Compared to adalimumab, secukinumab was associated with higher total costs and a greater number of QALYs over the model time horizon, which resulted in an ICER of £5680 per QALY gained for secukinumab versus adalimumab. The use of biosimilar prices for etanercept and infliximab did not meaningfully alter the results for secukinumab versus these TNFis. The fully incremental analysis found all interventions other than secukinumab, adalimumab (the least costly intervention) and infliximab (biosimilar) to be dominated or extendedly dominated. The ICER for secukinumab versus adalimumab was £5680 per QALY gained, and the ICER for infliximab (biosimilar) versus secukinumab was £1,147,641 per QALY gained.

In both populations, differences in total cost were largely due to biologic costs (see Table 9; Electronic Supplementary Material).

Sensitivity and Scenario Analyses {#Sec18}
---------------------------------

In both subpopulations, the model parameters associated with HAQ changes were generally the most influential factors on cost effectiveness results. Tornado plots for secukinumab versus comparators in the 1 prior csDMARD and ≥ 2 prior csDMARDs subpopulations are presented in Fig. [2](#Fig2){ref-type="fig"} and Fig. 5 (Electronic Supplementary Material), respectively. The 95% confidence intervals for incremental results from the probabilistic analysis are provided in Table [2](#Tab2){ref-type="table"} and suggest that the model results are generally robust to combined uncertainty in parameter values. Figure [3](#Fig3){ref-type="fig"} shows the scatter plot of all probabilistic results for secukinumab versus SoC in the 1 prior csDMARD subpopulation (for the ≥ 2 prior csDMARDs subpopulation, see Fig. 6 in the Electronic Supplementary Material). The probability of secukinumab having the highest net monetary benefit compared to all comparators was 48.9% and 88.9% in the 1 prior csDMARD and ≥ 2 prior csDMARDs subpopulations, respectively, when one QALY was valued at between £20,000 and £30,000. Cost effectiveness acceptability curves are presented in Fig. [4](#Fig4){ref-type="fig"} and Fig. 7 (Electronic Supplementary Material) for the 1 prior csDMARD and ≥ 2 prior csDMARDs subpopulations, respectively.Fig. 2One-way sensitivity analysis in the 1 prior csDMARD subpopulation: tornado plot for secukinumab vs SoC. A single QALY was valued at £30,000. *csDMARD* conventional systemic disease-modifying anti-rheumatic drug, *HAQ* Health Assessment Questionnaire, *PASI* Psoriasis Area Severity Index, *PsA* psoriatic arthritis, *PsARC* Psoriatic Arthritis Response Criteria, *QALY* quality-adjusted life year, *SEC* secukinumab, *SoC* standard of care, *Yr* year Table 2Probabilistic cost effectiveness results (with incremental results for secukinumab vs each comparator) \[average (95% confidence interval)\](a) 1 prior csDMARDInterventionTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsSEC89,785 (89,099--90,471)7.824 (7.776--7.872)SoC61,423 (60,695--62,150)6.893 (6.838--6.948)28,362 (28,063--28,661)0.931 (0.916--0.946)(b) ≥ 2 prior csDMARDsInterventionTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsSEC92,948 (92,259 to 93,638)8.089 (8.042 to 8.136)ADA90,705 (89,985 to 91,424)7.733 (7.685 to 7.782)2445 (1813 to 2675)0.356 (0.339 to 0.372)CZP100,947 (100,230 to 101,664)8.014 (7.968 to 8.061)− 7999 (− 8491 to − 7506)0.075 (0.057 to 0.092)ETN (biosimilar)96,371 (95,703 to 97,040)8.093 (8.046 to 8.140)− 3423 (− 3850 to − 2996)− 0.004 (− 0.021 to 0.013)GOL103,955 (103,089 to 104,820)7.803 (7.755 to 7.852)− 11,006 (− 11,639 to − 10,373)0.285 (0.267 to 0.304)INF (biosimilar)122,810 (122,010 to 123,610)8.123 (8.076 to 8.169)− 29,862 (− 30,433 to − 29,291)− 0.034 (− 0.050 to − 0.018)Incremental results are presented for SEC vs comparator(s)*ADA* adalimumab, *CZP* certolizumab pegol, *csDMARD* conventional systemic disease-modifying anti-rheumatic drug, *ETN* etanercept, *GOL* golimumab, *INF* infliximab, *QALY* quality-adjusted life year, *SEC* secukinumab, *SoC* standard of care Fig. 3Probabilistic results in the 1 prior csDMARD subpopulation: scatter plot for secukinumab vs SoC. *csDMARD* conventional systemic disease-modifying anti-rheumatic drug, *QALY* quality-adjusted life year, *SoC* standard of care, *WTP* willingness to pay Fig. 4Probabilistic results in the 1 prior csDMARD subpopulation: cost effectiveness acceptability curve for secukinumab vs SoC. *csDMARD* conventional systemic disease-modifying anti-rheumatic drug, *SEC* secukinumab, *SoC* standard of care

The ICERs for secukinumab versus comparators in each of these scenario analyses are presented in Table [3](#Tab3){ref-type="table"} (1 prior csDMARD) and Table 10 (≥ 2 prior csDMARDs; Electronic Supplementary Material). In the majority of scenarios explored, secukinumab was associated with an ICER \< £30,000 per QALY gained (or an ICER in the south-west quadrant \> £30,000 per QALY gained) versus each comparator and secukinumab at list price was still dominant compared to certolizumab pegol and golimumab when the PASs for these comparators were included in the ≥ 2 prior csDMARDs subpopulation. Results varied when considering different response definitions (i.e. PsARC and PASI) and on modelling of a second-line biologic. Reducing the time horizon to 10 years and assuming that HAQ rebound was equal to natural history resulted in considerably higher ICERs than in the base case analysis in the 1 prior csDMARD subpopulation.Table 3Scenario analyses: ICERs for the 1 prior csDMARD population (secukinumab vs SoC)\#Variable/assumption explored (base case)ScenarioICER (£ per QALY)Base case28,7481aTime horizon (40 years)10 years56,7051b20 years36,2721c52 years28,7012aResponse definition (PsARC only)PsARC and PASI ≥ 5026,6582bPsARC and PASI ≥ 7527,6542cPsARC and PASI ≥ 9031,2263Adjust HAQ for placebo (yes)No25,1104Adjust PASI for placebo (yes)No28,6805HAQ rebound (equal to initial gain)HAQ rebound is equal to natural history at the time of discontinuation^a^49,1496Utility source (FUTURE 2)Rodgers et al.16,522*csDMARD* conventional systemic disease-modifying anti-rheumatic drugs, *HAQ* Health Assessment Questionnaire, *ICER* incremental cost effectiveness ratio, *PASI* Psoriasis Area Severity Index, *PsARC* Psoriatic Arthritis Response Criteria, *SoC* standard of care^a^HAQ rebounds to the level and subsequent trajectory it would have been if there had been no initial response, as described by Rodgers et al. \[[@CR20]\]

Discussion {#Sec19}
==========

Based on the deterministic results of the analysis, decision makers may consider secukinumab 150 mg to represent a cost-effective use of UK NHS resources for patients with active PsA who are TNFi-naive and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to prior csDMARDs. The inclusion of separate analyses for patients according to the number of prior csDMARDs has allowed cost effectiveness to be evaluated at specific stages of the treatment pathway.

Results from the 1 prior csDMARD subpopulation, in which secukinumab was shown to have an ICER of less than £30,000 per QALY gained versus SoC, should be of interest to clinicians and payers in the UK given the recent clinical guideline recommendations for the use of biologics after an inadequate response to one prior csDMARD \[[@CR7], [@CR8]\]. In the ≥ 2 prior csDMARDs subpopulation, secukinumab was shown to dominate biologic comparators, including golimumab, certolizumab pegol and etanercept. The cost effectiveness of secukinumab versus infliximab and etanercept was also demonstrated when the prices for these comparators were based on biosimilar products. The availability of a confidential PAS discount for secukinumab in the UK further strengthens the case for cost effectiveness in both subpopulations \[[@CR15]\]. In conducting the analysis from a UK perspective and using UK guidelines and NICE recommendations to inform the model, the analyses are most relevant to the UK NHS. Analyses using other country perspectives (e.g. Canada) have been published elsewhere \[[@CR13]\].

The results of the cost effectiveness analysis were seen to be generally robust to changes in model parameters and assumptions, as demonstrated in probabilistic sensitivity analyses and a number of scenario analyses. In cases where cost effectiveness results were seen to differ considerably between base case and scenario analyses (e.g. time horizon and HAQ rebound assumptions in the 1 prior csDMARD subpopulation and response definition in the ≥ 2 prior csDMARDs subpopulation), the choice of base case assumptions was consistent with previous economic evaluations \[[@CR14], [@CR20]\]. As shown in probabilistic analyses, uncertainty in the cost effectiveness results was higher in the 1 prior csDMARD subpopulation.

The decision model is based on a well-established model structure that characterises the impact of biologics on both the skin and arthritic components of PsA. Another strength of the model is the use of clinical evidence derived from patient-level data for secukinumab and an SLR for comparators. Despite the comprehensiveness of the review, a number of assumptions were required for some clinical parameters due to limited published data for comparators. The inclusion of TNFi-experienced patients was a major source of between-trial variation and it is likely that treatment response in the overall population of more recent trials (such as FUTURE 2), which included TNFi-experienced patients, would be affected by the inclusion of these patients \[[@CR11]\]. Sequencing scenario analyses were also restricted by the lack of published data for comparator biologics in TNFi-experienced patients, hence the modelling of only first-line biologics in the base case analysis.

The results from the 1 prior csDMARD analysis are consistent with those from the UK cost effectiveness analysis presented by Corbett et al., in which secukinumab 150 mg was reported to have ICERs versus SoC of less than £30,000 per QALY in the relevant 1 prior csDMARD subpopulations (no psoriasis or mild to moderate psoriasis in Corbett et al. \[[@CR14]\]). Although secukinumab 150 mg was associated with lower costs versus other biologics in the relevant ≥ 2 prior csDMARDs subpopulations in both Corbett et al. and here, in Corbett et al., secukinumab was associated with fewer QALYs versus other biologics \[[@CR14]\]. Differences in total QALYs in the ≥ 2 prior csDMARDs subpopulation are likely to reflect differences in the NMAs utilised in each model \[[@CR14]\]. Other differences that may have affected results include the use of different utilities; the consideration of individual psoriasis severity subgroups by Corbett et al.; and the use of treatment sequencing in the base case analysis of Corbett et al. \[[@CR14]\]. Although using an established model framework, this economic evaluation makes use of alternative sources of inputs, including a novel utility algorithm which included baseline EQ-5D, age, gender and TNFi status as coefficients, and explores a simple approach to treatment sequencing in which the relative use of alternative biologics, with either unchanged or waned efficacy in the second-line setting, is considered. Results from these scenarios differed to the base case, with secukinumab dominant versus adalimumab but no longer dominant versus etanercept, thus demonstrating the impact of treatment sequencing on cost effectiveness results. Neither this model nor Corbett et al. incorporated the long-term benefits that biologics, such as secukinumab, may have in delaying or preventing the occurrence of structural joint damage associated with PsA \[[@CR14], [@CR33]\]. Furthermore, assumptions were required in both models regarding changes over time in PASI and HAQ, raising a potential need for further consideration of how the long-term effects of biologics can be most appropriately captured in cost effectiveness models.

Conclusion {#Sec20}
==========

Based on the evaluation here, secukinumab 150 mg at list price may be considered cost effective for PsA patients in the UK who are TNFi-naive and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to either one or two or more prior csDMARDs. The availability of data for all biologics at each stage of the treatment pathway would reduce uncertainties in the cost effectiveness analyses of biologics after prior csDMARDs.
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